Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa

Basit Öğe Kaydı
dc.authorscopusid57219209857
dc.authorscopusid37092966400
dc.authorscopusid57203264025
dc.authorscopusid9036191300
dc.authorscopusid35885183600
dc.authorscopusid6602303657
dc.authorscopusid7004473191
dc.contributor.authorUlusoy Severcan, Ezgi
dc.contributor.authorGünaydın, Nurşen Ciğerci
dc.contributor.authorHekimci Özdemir, Hamiyet
dc.contributor.authorGülen, Figen
dc.contributor.authorKavaklı, Kaan
dc.contributor.authorTanaç, Remziye
dc.contributor.authorDemir, Esen
dc.date.accessioned2022-05-11T14:37:15Z
dc.date.available2022-05-11T14:37:15Z
dc.date.issued2020
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground:Recombinant factor VIIa (rFVIIa) is a highly purified recombinant protein. It is approved for the treatment and prevention of bleeding episodes associated with congenital factor VII deficiency, congenital hemophilia with inhibitors, and Glanzmann's thrombasthenia. The most commonly reported adverse events are thrombolytic in nature. In this report, we present a successful desensitization protocol administered to an infant with a history of anaphylaxis to rFVIIa. Case:A male infant with a history of gingival bleeding at the age of 6 months was diagnosed with factor VII deficiency with a factor VII level of 1%. His sister also had diagnosis of factor VII deficiency. Our patient was hospitalized at 10 months of age with generalized petechiae and bloody stools. Twenty minutes after administration of rFVIIa, he developed anaphylaxis that responded to epinephrine and supportive care. Subsequently he was evaluated at the allergy clinic, where a skin prick test with rFVIIa was negative. However, the intradermal skin test, applied with 1/1,000 (1 mu g/1 mL, 0.1 mL) dilution of rFVIIa, showed induration of 8 mm (positive reaction). Because there is no alternative treatment for factor VII deficiency, we developed a successful 13-step desensitization protocol with rFVIIa (NovoSeven(R)). Desensitization was performed an additional 2 times using the same protocol, one of which was for a head injury and the other for a swollen knee since the period between the doses was similar to 3 months. Conclusion:Allergic reactions, such as anaphylaxis can occur without prior exposure. This can be due to the high molecular weight and structural property of the biological agent. In this report, we present an effective desensitization protocol for an infant with a history of anaphylaxis to rFVIIa. Desensitization protocols in this age group should be carried out in a medical facility and with specialized staff and equipment prepared to care for anaphylaxis.
dc.identifier.doi10.1089/ped.2019.1130
dc.identifier.endpage162
dc.identifier.issn2151-321X
dc.identifier.issn2151-3228
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85091704727
dc.identifier.scopusqualityQ3
dc.identifier.startpage159
dc.identifier.urihttps://doi.org/10.1089/ped.2019.1130
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8636
dc.identifier.volume33
dc.identifier.wosWOS:000571400900012
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorGünaydın, Nurşen Ciğerci
dc.language.isoen
dc.publisherMary Ann Liebert, Inc
dc.relation.ispartofPediatric Allergy Immunology and Pulmonology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectdesensitization
dc.subjectdrug allergy
dc.subjectfactor VIIa
dc.subjectActivated Factor-Vii
dc.subjectFactor-Ix Deficiency
dc.subjectHypersensitivity Reactions
dc.subjectRapid Desensitization
dc.subjectDrug Hypersensitivity
dc.subjectSafety
dc.subjectChemotherapy
dc.subjectInhibitors
dc.subjectDiagnosis
dc.subjectAllergy
dc.titleSuccessful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8636.pdf
Boyut:
93.85 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu